See more : BHEEMA CEMENTS LTD. (BHEEMACEM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Dicerna Pharmaceuticals, Inc. (DRNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dicerna Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Showa Chemical Industry Co., Ltd. (4990.T) Income Statement Analysis – Financial Results
- Uni-President China Holdings Ltd (0220.HK) Income Statement Analysis – Financial Results
- Apollo Tyres Limited (APOLLOTYRE.NS) Income Statement Analysis – Financial Results
- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (PAC) Income Statement Analysis – Financial Results
- Supremex Inc. (SUMXF) Income Statement Analysis – Financial Results
Dicerna Pharmaceuticals, Inc. (DRNA)
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 205.38M | 109.34M | 45.71M | 36.98M | 41.69M | 43.97M | 29.45M | 11.56M | 11.57M | 10.71M |
| General & Administrative | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Cost & Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Interest Income | 6.01M | 7.54M | 2.10M | 539.00K | 235.00K | 188.00K | 63.00K | 4.00K | 2.00K | 3.00K |
| Interest Expense | 20.00K | 3.00K | 603.00K | 0.00 | 0.00 | 0.00 | 199.00K | 952.00K | 1.34M | 997.00K |
| Depreciation & Amortization | 2.22M | 1.25M | 774.00K | 778.00K | 840.00K | 727.00K | 848.00K | 523.00K | 551.00K | 474.00K |
| EBITDA | -110.51M | -119.20M | -87.48M | -59.27M | -58.67M | -62.11M | -46.89M | -17.04M | -8.23M | -7.09M |
| EBITDA Ratio | -67.26% | -498.67% | -1,416.39% | -2,602.99% | -19,889.15% | -33,756.52% | 0.00% | 0.00% | -117.29% | -89.59% |
| Operating Income | -113.21M | -128.19M | -61.22M | -60.59M | -59.75M | -63.03M | -45.10M | -17.38M | -9.25M | -7.61M |
| Operating Income Ratio | -68.90% | -536.25% | -991.26% | -2,660.83% | -20,253.56% | -34,253.80% | 0.00% | 0.00% | -131.86% | -96.27% |
| Total Other Income/Expenses | 461.00K | 7.73M | -27.63M | 539.00K | 235.00K | 188.00K | -2.84M | -1.14M | -871.00K | -943.00K |
| Income Before Tax | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Income Before Tax Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| Income Tax Expense | 481.00K | 7.73M | -27.03M | 539.00K | 235.00K | 188.00K | -2.64M | -188.00K | 471.00K | 54.00K |
| Net Income | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Net Income Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| EPS | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| EPS Diluted | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| Weighted Avg Shares Out | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
| Weighted Avg Shares Out (Dil) | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
2 Biotech Stocks ARK Invest Bought in June
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for LY3819469
Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform
Dicerna Announces Boehringer Ingelheim's Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement
Dicerna to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports